Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 1.69B P/E - EPS this Y 7.80% Ern Qtrly Grth -26.70%
Income 63.59M Forward P/E 9.09 EPS next Y 7.60% 50D Avg Chg -4.00%
Sales 690.31M PEG 0.44 EPS past 5Y 13.97% 200D Avg Chg -13.00%
Dividend N/A Price/Book 2.09 EPS next 5Y 10.80% 52W High Chg -38.00%
Recommedations 2.60 Quick Ratio 5.49 Shares Outstanding 46.13M 52W Low Chg 8.00%
Insider Own 2.03% ROA 3.96% Shares Float 45.63M Beta 0.84
Inst Own 116.46% ROE 7.54% Shares Shorted/Prior 5.75M/5.15M Price 36.71
Gross Margin 62.99% Profit Margin 9.21% Avg. Volume 569,017 Target Price 24.13
Oper. Margin 17.40% Earnings Date Oct 31 Volume 1,351,799 Change 1.97%
About Pacira BioSciences, Inc.

Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Pacira BioSciences, Inc. News
11/14/24 Pacira Announces 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
11/12/24 Pacira BioSciences to Participate in Fireside Chat at Two Upcoming Healthcare Conferences
11/07/24 Pacira Q3 Earnings Top, Revenues Miss Despite Exparel Sales Growth
11/07/24 Q3 2024 Pacira Biosciences Inc Earnings Call
11/07/24 Pacira BioSciences Inc (PCRX) Q3 2024 Earnings Call Highlights: Strong Financial Position ...
11/06/24 Pacira: Q3 Earnings Snapshot
11/06/24 Pacira BioSciences Reports Third Quarter 2024 Financial Results
11/04/24 Centers for Medicare and Medicaid Services (CMS) Establishes Additional Payment for iovera in Outpatient Settings
10/30/24 Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024
10/21/24 Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock?
10/21/24 Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer
10/07/24 Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
10/05/24 The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings
10/03/24 Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025
09/26/24 Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee
09/25/24 DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders
09/09/24 Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
08/09/24 Pacira BioSciences Comments on Ruling on EXPAREL Patent Litigation from U.S. District Court for the District of New Jersey
08/07/24 Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
08/01/24 Pacira BioSciences, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
PCRX Chatroom

User Image Paperpino Posted - 1 week ago

$PCRX https://www.stocktitan.net/news/PCRX/pacira-announces-104-week-safety-and-efficacy-data-following-local-lm10lasfna4k.html

User Image DonCorleone77 Posted - 2 weeks ago

$PCRX Pacira sees FY24 revenue $680M-$705M, consensus $692.72M Sees FY 24 Non-GAAP gross margin of 74% to 76%.

User Image DonCorleone77 Posted - 2 weeks ago

$PCRX Pacira reports Q3 EPS 79c, consensus 70c Reports Q3 revenue $ $168.6M, consensus $169.67M..."2024 continues to be highlighted by important progress across both our clinical pipeline and commercial portfolio of best-in-class opioid-sparing products that delivered solid third quarter sales," said Frank D. Lee, chief executive officer of Pacira BioSciences. "Looking at the remainder of the year, we intend to build on this momentum by advancing our strategy for long-term growth and value creation, which includes investing in a best-practice commercial organization and innovative pipeline of potentially transformational assets, such as PCRX-201." "The work we have completed this year positions us to enter 2025 from a new place of focus, commitment, and strategic strength. We are confident the investments we are making will support and expand our leadership in non-opioid pain management and ensure we are positioned for sustainable success," continued Mr. Lee.

User Image Scanners_Free Posted - 2 weeks ago

$PCRX BEAT TOP MISS SAALES

User Image Beginner999 Posted - 10/25/24

$PCRX no one liked it here

User Image hope_my_calls_print Posted - 1 month ago

$PCRX chart still looking pretty strong, we might get back to 20 here sooner than later. Was clear this was way overdone on the August drop.

User Image hope_my_calls_print Posted - 1 month ago

$PCRX yeah called this one a while ago that we'd bounce back to 17-18 range soon enough. Lots of nice momentum on the chart here!

User Image Following_the_trend Posted - 1 month ago

$PCRX Maybe some life in this one after all

User Image GoldKing23 Posted - 1 month ago

$PCRX https://seekingalpha.com/news/4156042-pacira-wins-exparel-medicare-j-code

User Image ChristaBoarts Posted - 09/30/24

$PCRX, a leader in non-opioid pain management, is advancing healthcare by providing innovative solutions for pain and surgical recovery. Powered by FAAS.

User Image Stock_Titan Posted - 09/26/24

$PCRX Pacira Announces the Presentation of 104-Week Safety and Efficacy Data Following Local Administration of PCRX-201 for Moderate to Severe Osteoarthritis of the Knee https://www.stocktitan.net/news/PCRX/pacira-announces-the-presentation-of-104-week-safety-and-efficacy-kbsj8oixgv80.html

User Image Byebyeshorts Posted - 2 months ago

$PCRX this is about to explode

User Image thomas01635 Posted - 08/30/24

$PCRX this is easy Money and nobody realize it

User Image hope_my_calls_print Posted - 08/30/24

$PCRX the bounce back from 11 was the easiest thing I've ever seen in my life. Will probably take some profits in the 17-18 range. Really wish I'd bet the farm on that trade though, balance sheet was just wwwaayyyyyyyy too good for this to be trading at 500m market cap.

User Image Beginner999 Posted - 08/26/24

$PCRX nice so far

User Image thomas01635 Posted - 3 months ago

$PCRX 15 this week

User Image Beginner999 Posted - 3 months ago

$PCRX slowly but surely

User Image hope_my_calls_print Posted - 3 months ago

$PCRX I don't know how much above 15 we are going here, but we are going back to 15 in short order. The balance sheet is just way too strong for this to sit in the 12-14 range.

User Image insiderbuyingselling Posted - 3 months ago

$PCRX new insider buying: 1512 shares. http://insiderbuyingselling.com/?t=PCRX

User Image LXP Posted - 3 months ago

$PCRX my hospital just took exparel off formulary and doctors are upset. Not sure if this is a trend across academic centers. Will try to dive into it a bit if I have some time

User Image PenkeTrading Posted - 3 months ago

I found you an Oversold RSI (Relative Strength Index) on the daily chart of Pacira Pharmaceuticals Inc. Is that bullish or bearish? $PCRX #PCRX #nasdaq #tradingsignals #technicalanalysis

User Image thomas01635 Posted - 3 months ago

$PCRX next week 14$

User Image Beginner999 Posted - 3 months ago

$PCRX going up slow

User Image D9612 Posted - 3 months ago

$PCRX in at 11.44 and 12.87. Looking for $16.10.

User Image hope_my_calls_print Posted - 3 months ago

$PCRX onwards to 15, we are going to fill the gap here over next couple weeks.

User Image thomas01635 Posted - 3 months ago

$PCRX

User Image NotHopeJustFacts Posted - 3 months ago

$PCRX it seems that 12/share is gonna be the old 20/share it used to trade at....

User Image FlexxSquad Posted - 3 months ago

$PCRX

User Image GrindTime Posted - 3 months ago

$PCRX little more?

User Image thomas01635 Posted - 3 months ago

$PCRX

Analyst Ratings
Jefferies Buy Sep 24, 24
Truist Securities Sell Aug 13, 24
RBC Capital Sector Perform Aug 12, 24
HC Wainwright & Co. Buy Aug 12, 24
Needham Buy Aug 12, 24
JP Morgan Underweight Aug 12, 24
Raymond James Outperform Jul 31, 24
RBC Capital Outperform Jul 31, 24
Needham Buy Jul 31, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Riker Lauren Bullaro Senior Vice Presiden.. Senior Vice President, Finance Jul 05 Sell 38.91 643 25,019 22,687 07/07/23
WINSTON ROY Chief Medical Office.. Chief Medical Officer Jun 06 Sell 38.43 3,636 139,731 41,356 06/07/23
Williams Kristen Marie Chief Administrative.. Chief Administrative Officer Jun 06 Sell 38.43 2,658 102,147 20,892 06/07/23
STACK DAVID M CEO and Chairman CEO and Chairman Jun 06 Sell 38.43 10,384 399,057 153,781 06/07/23
SLONIN JONATHAN Chief Clinical Offic.. Chief Clinical Officer Jun 06 Sell 38.43 961 36,931 36,323 06/07/23
Riker Lauren Bullaro Senior Vice Presiden.. Senior Vice President, Finance Jun 06 Sell 38.43 1,207 46,385 19,053 06/07/23
Reinhart Charles A. III Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 38.43 2,607 100,187 33,626 06/07/23
REINHARDT MAX President, Rest of W.. President, Rest of World Jun 06 Sell 38.43 2,153 82,740 29,225 06/07/23
MOLLOY ANTHONY Chief Lgl & Complian.. Chief Lgl & Compliance Officer Jun 05 Sell 38.41 6,788 260,727 12,877 06/07/23
McLoughlin Dennis Chief Customer Offic.. Chief Customer Officer Jun 06 Sell 38.43 2,071 79,589 38,115 06/07/23
HASTINGS PAUL J Director Director Jun 05 Sell 38.339 580 22,237 6,599 06/07/23
GAUGLER DARYL Chief Operating Offi.. Chief Operating Officer Jun 05 Sell 38.53 3,052 117,594 21,539 06/07/23
Ellis Ronald J. Jr. Chief Strategy Offic.. Chief Strategy Officer Jun 06 Sell 38.43 2,276 87,467 30,909 06/07/23
Brege Laura Director Director Jun 05 Sell 38.74 600 23,244 9,547 06/07/23
GAUGLER DARYL Chief Operating Offi.. Chief Operating Officer May 31 Sell 39.08 2,500 97,700 24,591 06/02/23
GAUGLER DARYL Chief Operating Offi.. Chief Operating Officer May 31 Option 34 2,500 85,000 26,894 06/02/23
PACE GARY W Director Director May 11 Sell 41.78 5,015 209,527 139,675 05/15/23
PACE GARY W Director Director May 11 Option 29.9 7,000 209,300 144,690 05/15/23
MOLLOY ANTHONY Chief Lgl & Complian.. Chief Lgl & Compliance Officer Jan 04 Sell 38.7 704 27,245 19,450 01/06/23
SLONIN JONATHAN Chief Clinical Offic.. Chief Clinical Officer Jul 05 Sell 57.188 924 52,842 37,387 07/07/22
STACK DAVID M CEO and Chairman CEO and Chairman Jun 06 Sell 60.81 25,793 1,568,472 142,251 06/08/22
WINSTON ROY Chief Medical Office.. Chief Medical Officer Jun 06 Option 34.38 6,250 214,875 50,607 06/08/22
WINSTON ROY Chief Medical Office.. Chief Medical Officer Jun 06 Sell 61.96 17,546 1,087,150 35,160 06/08/22
Williams Kristen Marie Chief Administrative.. Chief Administrative Officer Jun 06 Sell 60.44 8,618 520,872 13,650 06/08/22
SLONIN JONATHAN Chief Clinical Offic.. Chief Clinical Officer Jun 06 Sell 61.37 362 22,216 28,197 06/08/22
Riker Lauren Bullaro Senior Vice Presiden.. Senior Vice President, Finance Jun 06 Sell 61.37 1,150 70,576 14,002 06/08/22
Reinhart Charles A. III Chief Financial Offi.. Chief Financial Officer Jun 06 Sell 61.37 2,516 154,407 28,283 06/08/22
REINHARDT MAX President, Rest of W.. President, Rest of World Jun 06 Sell 61.69 5,250 323,872 24,400 06/08/22
LARANJEIRA CHARLES ANTHONY Chief Technical Offi.. Chief Technical Officer Jun 06 Sell 60.73 7,750 470,658 25,852 06/08/22
MOLLOY ANTHONY Chief Lgl & Complian.. Chief Lgl & Compliance Officer Jun 06 Sell 60.38 5,550 335,109 12,000 06/08/22
McLoughlin Dennis Chief Customer Offic.. Chief Customer Officer Jun 06 Sell 61.37 2,140 131,332 31,820 06/08/22
GAUGLER DARYL Chief Operating Offi.. Chief Operating Officer Jun 06 Sell 61.37 1,106 67,875 11,494 06/08/22
Froimson Mark Director Director May 09 Sell 59.37 1,000 59,370 4,908 05/11/22
STACK DAVID M CEO and Chairman CEO and Chairman Apr 28 Option 10.81 22,500 243,225 168,044 05/02/22
REINHARDT MAX President, Rest of W.. President, Rest of World Apr 21 Option 42.54 12,500 531,750 39,474 04/25/22
REINHARDT MAX President, Rest of W.. President, Rest of World Apr 21 Sell 73.25 9,824 719,608 29,650 04/25/22
REINHARDT MAX President, Rest of W.. President, Rest of World Apr 18 Option 42.54 37,500 1,595,250 36,738 04/20/22
REINHARDT MAX President, Rest of W.. President, Rest of World Apr 18 Sell 73.26 28,026 2,053,185 26,974 04/20/22
MOLLOY ANTHONY Chief Lgl & Complian.. Chief Lgl & Compliance Officer Apr 06 Option 39.32 22,500 884,700 40,050 04/08/22
MOLLOY ANTHONY Chief Lgl & Complian.. Chief Lgl & Compliance Officer Apr 06 Sell 77 22,500 1,732,500 17,550 04/08/22
STACK DAVID M CEO and Chairman CEO and Chairman Mar 31 Option 10.81 22,500 243,225 145,544 04/05/22
Williams Kristen Marie Chief Administrative.. Chief Administrative Officer Mar 21 Option 43.18 7,253 313,185 29,521 03/23/22
Williams Kristen Marie Chief Administrative.. Chief Administrative Officer Mar 21 Sell 72.67 7,253 527,076 22,268 03/23/22
Riker Lauren Bullaro Senior Vice Presiden.. Senior Vice President, Finance Mar 10 Option 10.81 9,300 100,533 24,452 03/14/22
Riker Lauren Bullaro Senior Vice Presiden.. Senior Vice President, Finance Mar 10 Sell 71.55 9,300 665,415 15,152 03/14/22
PACE GARY W Director Director Mar 03 Option 10.81 7,000 75,670 136,530 03/07/22
LONGENECKER JOHN P PHD Director Director Mar 03 Option 10.81 7,000 75,670 25,823 03/07/22
LONGENECKER JOHN P PHD Director Director Mar 03 Sell 71.74 7,000 502,180 18,823 03/07/22
PACE GARY W Director Director Feb 28 Option 11.02 30,000 330,600 130,889 03/01/22
PACE GARY W Director Director Feb 28 Sell 67.29 30,000 2,018,700 129,530 03/01/22